A recent blog from the Alzheimer’s Association discusses growing interest in GLP-1 receptor agonists, medications commonly used for diabetes and weight loss, as possible treatments for Alzheimer’s disease. Drugs such as semaglutide (sold as Ozempic and Wegovy), liraglutide, and tirzepatide may have effects beyond blood sugar control, including reducing brain inflammation, improving blood vessel health, and protecting neurons.

The article highlights two major Phase 3 clinical trials, EVOKE and EVOKE+, which are studying whether semaglutide can slow progression in people with early Alzheimer’s disease. Because semaglutide is already FDA-approved for diabetes and obesity, successful results could speed up access for Alzheimer’s patients compared with developing an entirely new drug.

Researchers are also exploring other GLP-1 medications and possible combination therapies with anti-amyloid drugs already approved for Alzheimer’s. While early findings are encouraging, experts stress that more evidence is needed before these drugs can be recommended for dementia treatment. Patients are advised not to start or stop GLP-1 medications specifically for Alzheimer’s without medical guidance.

The article emphasizes cautious optimism, noting that ongoing research may open new avenues for preventing or slowing cognitive decline in the future.